17 results
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
in the EEA prior to May 20, 2004, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest … health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MAA under the accelerated
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
in the EEA prior to May 20, 2004, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest … health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MAA under the accelerated
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
in the EEA prior to May 20, 2004, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest … health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MAA under the accelerated assessment
424B4
CHRO
Chromocell Therapeutics Corp.
20 Feb 24
Prospectus supplement with pricing info
5:30pm
. Most recently, on March 10, 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, which … innovation, or if its authorization would be in the interest of public health in the EEA. If pursuing marketing authorization of a lead compound
424B4
CHRO
Chromocell Therapeutics Corp.
20 Feb 24
Prospectus supplement with pricing info
5:28pm
Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. Similarly, on March 12 … a new active substance not authorized in the EEA prior to May 20, 2004, is a significant therapeutic, scientific or technical innovation, or if its
DRS/A
vcs1cht
17 Oct 22
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next